Malaria Medication Could Treat Polycystic Ovary Syndrome According To New Study
A promising breakthrough in the treatment of Polycystic Ovary Syndrome (PCOS) has emerged from an unexpected source: artemisinin, a drug traditionally used for malaria treatment.
PCOS, currently affecting approximately 10% of reproductive-age women worldwide, is characterized by hormonal imbalances that can lead to irregular menstrual cycles, infertility, and other symptoms such as acne and excess body hair.
Recent studies, including a small clinical trial involving 19 women with PCOS, have shown that artemisinin derivatives, specifically artemether and dihydroartemisinin, effectively improve symptoms associated with the condition. These derivatives not only improved the regularity of menstrual cycles but also significantly reduced elevated testosterone levels—a common issue in individuals with PCOS.
Dr. Qi-Qun Tang and his team at Fudan University in Shanghai, China, observed these benefits during their investigations into artemisinin's effects on metabolic disorders. Their research, initially conducted on rats with PCOS-like symptoms, demonstrated that artemether decreased androgen production in the ovaries by targeting specific enzymes involved in hormone synthesis. Similar clinical trials confirmed these findings, showing a reduction in serum testosterone levels and improvements in ovarian health markers among participants.
However, despite these promising results, challenges remain. PCOS is a multifaceted disorder with metabolic implications, including insulin resistance, which contributes to its complexity. While artemisinin derivatives show promise in managing hormonal symptoms, they did not improve insulin sensitivity in the women studied.
Dr. Andrea Dunaif, an endocrinologist specializing in PCOS at the Icahn School of Medicine at Mount Sinai called for conducting larger, placebo-controlled trials to validate these initial findings to assess the long-term efficacy and safety of artemisinin derivatives. She also cautioned against self-medication with artemisinin products available online.
And, of course, the potential of artemisinin to become a mainstream PCOS treatment hinges on pharmaceutical industry interest and regulatory approvals which are notoriously questionable.
While artemisinin seems to be a potential option for managing PCOS symptoms, further research and longer clinical trials are needed to fully understand its potential side effects. Hopefully, that means more progress will be made in treating this common yet challenging condition affecting millions of women worldwide.
Evie deserves to be heard. Support our cause and help women reclaim their femininity by subscribing today.